RecruitingPhase 2NCT06050668

Essential Amino Acid Supplementation for Femoral Fragility Fractures

MEND Repair & Recover Clinical Trial


Sponsor

Michael C Willey

Enrollment

60 participants

Start Date

Jun 17, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.


Eligibility

Min Age: 65 Years

Inclusion Criteria6

  • Hospital inpatient
  • Age ≥ 65 years old on admission
  • Low-energy mechanism of injury
  • Diagnosis of femur fracture (OTA 31, 32, or 33 fracture)
  • Indicated for surgical fixation
  • Able to provide informed consent

Exclusion Criteria8

  • Part of a vulnerable population (ex: Incarcerated, Non-English speaking)
  • Cognitive impairment (MMSE score ≤ 17)
  • Electrical medical implant (ex: Pacemaker/Defibrillator, Left Ventricular Assist Device, Cochlear implant, Insulin pump, Pain medication pumps, Spinal cord stimulator)
  • Non-ambulatory prior to injury
  • Inability to consume an oral diet or allergy to supplement ingredients (ex: milk allergy)
  • Concern for inability to complete follow-up
  • Hemi or total arthroplasty (joint replacement)
  • Patients with a historical diagnosis of chronic kidney disease (CKD)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTEssential Amino Acid Supplementation

Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)


Locations(2)

University of Iowa Health Care

Iowa City, Iowa, United States

Slocum Center for Orthopedics & Sports Medicine

Eugene, Oregon, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06050668


Related Trials